Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer by Narumol Trachu, Thanyanan Reungwetwattana, Jennis Meanwatthana, Chonlaphat Sukasem, Teerapat Majam, Wacharapol Saengsiwaritt, Jiraphun Jittikoon, Wanvisa Udomsinprasert

Subjects: Get full text

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study by Jixian Li, Xiang Zhan, Mengqing Shao, Renya Zeng, Jianan Li, Hui Zhu, Alei Feng, Zhe Yang, Wang Jing

Subjects: Get full text

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system by Yaqian Tan, Qi Song

Subjects: “…Osimertinib…”
Get full text

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC by Yingqi Xu, Yidan Zhang, Hongping Jin, Hua Zhong, Jianlin Xu, Yuqing Lou, Runbo Zhong

Subjects: Get full text

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer by Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Karen L. Reckamp, Kamya Sankar, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins, Katelyn M. Atkins

Subjects: “…osimertinib…”
Get full text

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms by Xin Liao, Tingting He, Xiong Wan, Pian Liu, Jing Li, Yong He, Yubo Wang

Subjects: Get full text

Tumor-associated macrophages derived exosomal circPLK1 promotes resistance to EGFR inhibitor osimertinib in non-small cell lung cancer by Chuankui Li, Xinyu Sun, Zuyi Wang

Subjects: Get full text

Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer by Mostafa Aglan, Erin Spyropoulous, Joel Oster, Paul J. Hesketh, A.J. Piper-Vallillo

Subjects: Get full text

Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report by Jian Wang, Jian Wang, Xinying Dong, Yangxin Liu, Keying Lin, Jianxin Chen

Subjects: Get full text

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report by Aditi Singh, MBBS, MPH, Arthi Sridhar, MBBS, Aastha Poddar, MBBS, Anastasios Dimou, MD, Kaushal Parikh, MBBS, Mohamed Shanshal, MD, Anna Schwecke, APRN, CNP, MS, Nicole Moffett, APRN, CNP, MSN, Manish R. Patel, DO, Aaron S. Mansfield, MD, Konstantinos Leventakos, MD, PhD

Subjects: Get full text

Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report by Kenta Manabe, Kazuhiko Shien, Shinichi Furukawa, Tomoya Seno, Kousei Ishimura, Shin Tanaka, Ken Suzawa, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka

Subjects: “…Osimertinib…”
Get full text

Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer by Kenneth K. W. To, Kwong‐Sak Leung, William C. Cho

Subjects: Get full text

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study by Yu Hua, Minghui Liu, Boshi Li, Hongbing Zhang, Zihe Zhang, Yanan Wang, Jinghao Liu, Xin Li, Yongwen Li, Sen Wei, Hongyu Liu, Jun Chen

Subjects: Get full text

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example by Bing Wei, Chengzhi Zhao, Jun Li, Jiuzhou Zhao, Pengfei Ren, Ke Yang, Chi Yan, Rui Sun, Jie Ma, Yongjun Guo

Subjects: Get full text

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature by Marianna Peroni, MD, Alessandro Leonetti, MD, PhD, Roberta Minari, MSc, PhD, Michela Verzè, MSc, Letizia Gnetti, MD, Lorena Bottarelli, MSc, PhD, Cinzia Azzoni, MSc, PhD, Marco Galaverni, MD, Nicola Simoni, MD, Gabriele Missale, MD, Elisabetta Biasini, MD, Marcello Tiseo, MD, PhD

Subjects: Get full text

Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer by Martin Johnson, Yu‐Wei Lin, Henning Schmidt, Mikael Sunnaker, Eline Van Maanen, Xiangning Huang, Yuri Rukazenkov, Helen Tomkinson, Karthick Vishwanathan

Subjects: Get full text

Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC by Angelos Vasilopoulos, BS, Alexander Pohlman, MD, Ayham Odeh, MD, K. Robert Shen, MD, Julia M. Coughlin, MD, Zaid M. Abdelsattar, MD, MS, FACS

Subjects: Get full text

Electrocardiographic changes in QTc interval and other parameters associated with osimertinib therapy by Yilin Pan, Yilin Pan, Kexin Peng, Yichuan Jiang, Ping Yang, Beibei Du, Yuquan He

Subjects: “…osimertinib…”
Get full text

Solitary fibular metastasis from lung adenocarcinoma with gene mutation: a case report by Jiechen Chen, Ahmad Alkhatatbeh, Yinbing Lin, Xiaolin Lu, Bin Chen, Hongjiang Chen, Xiaohui Lu, Hansheng Wu, Jun Hu

Subjects: Get full text

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report by Daphnée Demers, Marie Florescu

Subjects: Get full text